Background
Virus like particles (VLPs) are a type of nanoscale particles similar to viruses, with structures similar to real viruses but without viral genes, thus possessing high biological safety. VLPs are particles formed by assembling viral structural proteins, which are similar in size and shape to natural viruses. VLPs have the immunogenicity of natural viruses, but they do not have infectivity or replication ability. By using the VLP technology platform, membrane proteins with natural conformations can be displayed on the surface of these virus like particles. This ability makes their application in immunity and antibody screening valuable.
Yeasen has successfully developed a series of full-length multi transmembrane protein products for VLP display. The targets include Claudin 18.2, GPRC5D, CCR8, CD20, and various other transmembrane proteins. Yeasen has overcome the technical barriers of difficulty and low solubility in preparing such proteins.
Production methods of VLP technology platform
The VLP technology platform can be produced through various host cell systems, such as insect cells, mammalian cells, and plant cells. Compared to insect and plant cell systems, mammalian cell expression systems are closer to the physiological environment of human cells, and therefore have higher fidelity in protein translation, modification, and folding. This makes VLP expressed in mammalian cells more similar to the immunogenicity and biological activity of natural viruses.
Yeasen has improved its production process based on the VLP technology platform of mammalian cell expression system, which can significantly increase expression levels and reduce cell toxicity.
Advantages of VLPs in expressing recombinant proteins
Highly mimicking the structure of natural viruses: The size, shape, and spatial conformation of viral surface proteins are very similar to those of natural viruses. This enables VLPs to highly simulate the behavior of natural viruses in living organisms, effectively inducing immune responses.
Security: As VLPs do not contain viral genes, they do not have infectivity or replication ability, and therefore have high biological safety.
High immunogenicity: The multivalent nature of VLPs and their high imitation of natural viral surface proteins give them high immunogenicity. In vaccine research, VLPs can effectively activate the immune responses of B and T cells, thereby producing a strong immune protective effect.
Strong plasticity: Through genetic engineering, exogenous antigens can be fused into the structural proteins of VLPs to generate chimeric VLPs. This design enables exogenous antigens to be presented in the form of VLPs in the body, thereby enhancing immunogenicity.
VLPs have many advantages in expressing recombinant proteins, making them widely applicable in fields such as vaccine research, drug delivery, and immune regulation.
The advantages of VLPs in expressing transmembrane proteins
Spatial conformation maintenance: Transmembrane proteins have complex three-dimensional structures, and their functions usually rely on correct spatial conformation on the cell membrane. Compared with other expression systems, VLPs can better simulate the membrane environment of natural viruses and help maintain the correct spatial conformation and biological activity of transmembrane proteins.
Protein translation and modification: VLPs can be produced through mammalian cell expression systems, which have high fidelity in protein translation, folding and modification, facilitating the correct expression and function of transmembrane proteins.
Enhanced immunogenicity: VLPs can serve as immunogen delivery vehicles, presenting transmembrane proteins to the immune system in the form of natural viruses. This method can improve the immunogenicity of transmembrane proteins and stimulate stronger immune responses.
Functional screening: Using VLPs to express transmembrane proteins can facilitate functional screening, such as determination of transmembrane protein affinity or optimization of antibody affinity. This helps to study the biological functions of transmembrane proteins and develop related drugs.
The advantages of VLPs in expressing transmembrane proteins can help solve key issues in transmembrane protein research, such as protein expression, functional screening, and immunogenicity.
Yeasen,s VLPs technology platform
Yeasen has specially built an enveloped VLP technology platform based on the HEK293 expression system. The prepared enveloped VLP displays correctly folded multiple-transmembrane proteins on its inherent vesicle membrane, demonstrating complete biological activity.
Advantages of VLP platform:
(1) Display the natural conformation of multiple transmembrane proteins with complete biological activity
(2) It can enhance immunogenicity and break the body's own immune tolerance
(3) The abundance of target antigens in envelope VLP is higher than that in overexpressing cells
(4) Can be used for immune/ELISA/SPR/BLI/CAR-T positivity detection, assisting in the discovery of lead molecules
Product Highlight
(1) Natural conformation: HEK293 eukaryotic expression , Full-length sequence, native structure and conformation
(2) High immunogenicity
(3) Comprehensive quality inspection: Comprehensive validation through DLS、SEC、ELISA、LAL and SPR
(4) High antigen abundance:VLP protein is pure、ensuring high purity
Application of VLP Protein
(1) Animal Immunization
(2) Antibody screening
(3) CMC method development
(4) In vivo pharmacodynamic and pharmacokinetic studies
(5) ELISA、SPR、BLI、Cell Assay
Product List
|
Cat |
Product name |
Specifications |
|
Recombinant Human CLDN18.1 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CLDN18.2 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CXCR1 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CXCR4 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human FZD10/Frizzled-10 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human FZD7/Frizzled-7 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GCGR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GHSR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GIPR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GLP1R Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GPR75 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human GPRC5D Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human LGR6 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human SLC7A11 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human SSR1 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human TSHR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human XCR1 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human LSHR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human A2AR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human C5AR Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CB1 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CB2 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CCR8 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CD20 Protein-VLP |
20μg/100μg/1mg |
|
|
Recombinant Human CLDN1/Claudin-1 Protein-VLP |
20μg/100μg/1mg |